A bold marketing move on weight-loss drugs sent HIMS stock soaring, but regulatory and industry backlash is mounting.

The settlement filed in Newark, N.J. federal court comes after similar settlements with Eli Lilly and Sanofi last year. It ...

Days after Vancouver’s Aspect Biosystems Ltd. landed US$115 million in Series B financing in early January, CEO Tamer Mohamed likely surprised many by telling BIV that he thought the investment ...

Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly is expanding the ...

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use ...

This week was loaded with earnings releases of many large drugmakers. Novo Nordisk NVO, Merck MRK, Pfizer PFE, Eli Lilly LLY, ...

This week was loaded with earnings releases of many large drugmakers. Novo Nordisk NVO, Merck MRK, Pfizer PFE, Eli Lilly LLY, AstraZeneca AZN and AbbVie announced their fourth-qua ...

Maxim lowered the firm’s price target on Viking Therapeutics (VKTX) to $70 from $120 and keeps a Buy rating on the shares after the company’s ...

It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their US ...

Evaluate’s latest analysis forecasts an $82 billion increase in major product revenues in 2025 – the largest annual growth ...

The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...